240 studies found for:    "Adenocarcinoma of lung"
Show Display Options
Rank Status Study
21 Recruiting Low-Dose Acetylsalicylic Acid in Treating Patients With Stage I-III Non-Small Cell Lung Cancer
Conditions: Adenocarcinoma of the Lung;   Recurrent Non-small Cell Lung Cancer;   Stage IA Non-small Cell Lung Cancer;   Stage IB Non-small Cell Lung Cancer;   Stage IIA Non-small Cell Lung Cancer;   Stage IIB Non-small Cell Lung Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer
Interventions: Drug: acetylsalicylic acid;   Other: laboratory biomarker analysis
22 Recruiting Registry Measuring the Impact of Adding RNA Expression Testing on Referral Decisions in Early Stage Lung Cancer Patients (ONC003_CT Surgeon Specific)
Conditions: Lung Cancer;   NSCLC;   Lung Adenocarcinoma
Intervention:
23 Active, not recruiting
Has Results
Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-Small Cell Lung Cancer
Conditions: Adenocarcinoma of the Lung;   Adenosquamous Cell Lung Cancer;   Bronchoalveolar Cell Lung Cancer;   Recurrent Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
Interventions: Drug: erlotinib hydrochloride;   Drug: paclitaxel;   Drug: carboplatin
24 Recruiting A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC
Conditions: Non-Small-Cell Lung Adenocarcinoma;   Non-small Cell Lung Cancer Stage IIIB;   Non-small Cell Lung Cancer Stage IV;   Non-small Cell Lung Cancer Metastatic
Interventions: Drug: Arm A: single agent docetaxel;   Drug: Arm B: Combination of ganetespib and docetaxel
25 Completed Sorafenib in BAC or Never-Smokers With Lung Adenocarcinoma
Condition: Lung Cancer
Intervention: Drug: sorafenib
26 Recruiting Comparison of Two Therapeutic Strategies in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) With Asymptomatic Brain Metastases
Conditions: Non-small Cell Lung Cancer Metastatic;   Non Epidermoid;   Non-small Cell Lung Cancer;   Adenocarcinoma of Lung Metastatic to Brain;   Cerebral Metastases;   Cerebral Radiotherapy;   Brain Radiotherapy;   Bevacizumab
Interventions: Drug: Cisplatin;   Drug: Pemetrexed;   Drug: Bevacizumab;   Radiation: Cerebral Radiotherapy
27 Completed Neoadjuvant Pemetrexed, Cisplatin and Bevacizumab in Unresectable, Locally Advanced Lung Adenocarcinoma
Condition: Lung Cancer
Intervention: Drug: Neoadjuvant Bevacizumab
28 Active, not recruiting Safety and Pharmacology Study of SNX-5422 in Subjects With Resistant Lung Adenocarcinoma
Condition: Cancer
Intervention: Drug: SNX-5422
29 Recruiting Intercalated Administration of PamCis With Gefitinib or Placebo as First Line Lung Adenocarcinoma in Never Smokers
Conditions: Non Small Cell Lung Cancer;   Adenocarcinoma
Interventions: Drug: Gefitinib;   Drug: Placebo;   Drug: Pemetrexed plusCIsplatin
30 Recruiting A Phase II Study to Assess Efficacy of Combined Treatment With Erlotinib (Tarceva) and Silybin-phytosome (Siliphos) in Patients With EGFR Mutant Lung Adenocarcinoma
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: Erlotinib;   Dietary Supplement: Silybin-phytosome
31 Recruiting Whole-Exome Sequencing (WES) of Cancer Patients
Conditions: Lung Adenocarcinoma;   Colon Adenocarcinoma
Intervention:
32 Recruiting Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer
Conditions: Adenocarcinoma of the Lung;   Adenosquamous Cell Lung Cancer;   Bronchoalveolar Cell Lung Cancer;   Large Cell Lung Cancer;   Recurrent Non-small Cell Lung Cancer;   Squamous Cell Lung Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer
Interventions: Drug: paclitaxel;   Drug: carboplatin;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy;   Radiation: volumetric-modulated arc therapy;   Drug: metformin hydrochloride;   Other: laboratory biomarker analysis
33 Recruiting Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers
Conditions: Adenocarcinoma of the Lung;   Extensive Stage Small Cell Lung Cancer;   Limited Stage Small Cell Lung Cancer;   Recurrent Non-small Cell Lung Cancer;   Recurrent Small Cell Lung Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
Intervention: Drug: Ponatinib
34 Terminated Bevacizumab, Paclitaxel, Carboplatin, and Radiation Therapy to the Chest in Treating Patients With Locally Advanced Non-Small Cell Lung Cancer
Conditions: Adenocarcinoma of the Lung;   Bronchoalveolar Cell Lung Cancer;   Large Cell Lung Cancer;   Stage II Non-small Cell Lung Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer
Interventions: Radiation: 3-dimensional conformal radiation therapy;   Drug: paclitaxel;   Biological: bevacizumab;   Drug: carboplatin;   Other: laboratory biomarker analysis
35 Recruiting Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination Chemotherapy in Treating Patients With Stage II-III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery
Conditions: Adenocarcinoma of the Lung;   Adenosquamous Cell Lung Cancer;   Large Cell Lung Cancer;   Recurrent Non-small Cell Lung Cancer;   Squamous Cell Lung Cancer;   Stage IIA Non-small Cell Lung Cancer;   Stage IIB Non-small Cell Lung Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer
Interventions: Radiation: hypofractionated radiation therapy;   Other: laboratory biomarker analysis;   Radiation: image-guided radiation therapy;   Drug: carboplatin;   Drug: paclitaxel;   Radiation: stereotactic body radiation therapy
36 Active, not recruiting MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy
Conditions: Adenocarcinoma of the Lung;   Adenosquamous Cell Lung Cancer;   Bronchoalveolar Cell Lung Cancer;   Large Cell Lung Cancer;   Recurrent Non-small Cell Lung Cancer;   Squamous Cell Lung Cancer
Interventions: Drug: Akt inhibitor MK2206;   Drug: erlotinib hydrochloride;   Other: laboratory biomarker analysis;   Other: pharmacological study
37 Completed
Has Results
Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Conditions: Adenocarcinoma of the Lung;   Adenosquamous Cell Lung Cancer;   Bronchoalveolar Cell Lung Cancer;   Large Cell Lung Cancer;   Non-small Cell Lung Cancer;   Recurrent Non-small Cell Lung Cancer;   Squamous Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
Interventions: Drug: cisplatin;   Biological: pegfilgrastim;   Drug: erlotinib hydrochloride;   Other: laboratory biomarker analysis;   Genetic: polymorphism analysis;   Other: pharmacogenomic studies;   Genetic: genetic linkage analysis;   Drug: docetaxel
38 Completed Surgery With or Without Chemotherapy in Treating Patients With Stage I Non-small Cell Lung Cancer
Conditions: Adenocarcinoma of the Lung;   Adenosquamous Cell Lung Cancer;   Bronchoalveolar Cell Lung Cancer;   Large Cell Lung Cancer;   Squamous Cell Lung Cancer;   Stage IB Non-small Cell Lung Cancer
Interventions: Drug: paclitaxel;   Drug: carboplatin;   Procedure: therapeutic conventional surgery
39 Completed Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer
Conditions: Adenocarcinoma of the Lung;   Adenosquamous Cell Lung Cancer;   Bronchoalveolar Cell Lung Cancer;   Large Cell Lung Cancer;   Squamous Cell Lung Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer
Interventions: Drug: paclitaxel;   Drug: carboplatin;   Drug: gefitinib;   Radiation: radiation therapy;   Other: laboratory biomarker analysis
40 Completed Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
Conditions: Adenocarcinoma of the Lung;   Adenosquamous Cell Lung Cancer;   Large Cell Lung Cancer;   Malignant Pleural Effusion;   Recurrent Non-small Cell Lung Cancer;   Squamous Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
Interventions: Drug: docetaxel;   Biological: cetuximab;   Drug: bortezomib

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years